Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?

被引:24
作者
Oh, Kyu-Bin [1 ]
Doherty, T. Mark [2 ]
Vetter, Volker [3 ]
Bonanni, Paolo [4 ]
机构
[1] GSK, Wavre, Belgium
[2] GSK, Brondby, Denmark
[3] GSK, Munich, Germany
[4] Univ Florence, Dept Hlth Sci, Florence, Italy
关键词
COVID-19; pandemic; infectious diseases; influenza; non-pharmaceutical interventions; norovirus; outbreaks; respiratory syncytial virus; resurgence; rhinovirus; vaccine-preventable diseases; RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; SEASONAL INFLUENZA; DISEASE; IMPACT; IMMUNIZATION; INFECTIONS; CHILDHOOD; CHILDREN; TRANSMISSION;
D O I
10.1080/14760584.2022.2117693
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plain Language Summary In the first months of the COVID-19 pandemic, the only methods available to slow the spread of the disease were non-pharmaceutical interventions, such as lockdowns, mask wearing, social distancing, school closures, and travel bans. Even after vaccines against COVID-19 became available, combinations of non-pharmaceutical interventions continued to be implemented by most countries, to various extents. Although these measures lowered the number of people who got sick before vaccines and therapies against COVID-19 were available, they also had other consequences for public health. The non-pharmaceutical interventions implemented worldwide have slowed or even stopped the spread of several infectious diseases: since 2020, fewer cases of flu, bronchiolitis, gastroenteritis, and other diseases were recorded compared to pre-pandemic times. This relatively long 2-year period during which people, especially children, were exposed to fewer infections might mean that their immune systems are less prepared to fight these diseases. In addition, vaccination against diseases other than COVID-19 dropped in the early months of the pandemic, meaning that the number of children and adults who are not protected against vaccine-preventable disease has potentially increased. Easing of COVID-19 restrictions has caused a comeback of some diseases against which no vaccine is available, sometimes with more cases than during the pre-pandemic years; there is a risk that this might happen with vaccine-preventable diseases as well. To prevent outbreaks, routine and catch-up vaccinations against other diseases besides COVID-19 should be encouraged and promoted. Introduction In the first months of the novel coronavirus (COVID-19) pandemic that begun in 2020, non-pharmaceutical interventions (NPIs) have been adopted worldwide. However, the effects of NPI implementation go beyond slowing the spread of COVID-19. Here, we review the non-intended effects that may have arisen from prolonged application of NPIs. Areas covered NPIs also affected the epidemiology of other infectious diseases, with unprecedentedly low circulation of several respiratory and gastrointestinal viruses being observed worldwide in 2020. While this was a welcome effect for already strained health-care systems, prolonged low exposure to pathogens may result in an increased pool of individuals susceptible to certain diseases. Out-of-season or unusually intense outbreaks of non-vaccine preventable diseases have already been documented as NPIs were gradually eased. In the context of widespread and important disruptions in national vaccination programs during the early phase of the pandemic, the risk of vaccine-preventable disease resurgence after NPIs are lifted cannot be excluded either. Expert opinion Awareness must be raised of the risk of vaccine-preventable disease resurgence, and efforts need to be made to mitigate this risk, where possible, by increasing vaccination coverage. Research and regulatory opportunities brought on by the COVID-19 pandemic should be seized.
引用
收藏
页码:1541 / 1553
页数:13
相关论文
共 116 条
  • [1] Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/52214-109X(20)30308-9, 10.1016/S2214-109X(20)30308-9]
  • [2] Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia
    Adegbija, Odewumi
    Walker, Jacina
    Smoll, Nicolas
    Khan, Arifuzzaman
    Graham, Julieanne
    Khandaker, Gulam
    [J]. COMMUNICABLE DISEASES INTELLIGENCE, 2021, 45
  • [3] Does the rise in seasonal respiratory viruses foreshadow the return of invasive pneumococcal disease this winter?
    Amin-Chowdhury, Zahin
    Bertran, Marta
    Sheppard, Carmen L.
    Eletu, Seyi
    Litt, David
    Fry, Norman K.
    Ladhani, Shamez N.
    [J]. LANCET RESPIRATORY MEDICINE, 2022, 10 (01) : E1 - E2
  • [4] Maternal vaccines during the Covid-19 pandemic:A qualitative interview study with UK pregnant women
    Anderson, Emma
    Brigden, Amberly
    Davies, Anna
    Shepherd, Emily
    Ingram, Jenny
    [J]. MIDWIFERY, 2021, 100
  • [5] [Anonymous], 2022, MEASL CAS AR SPIK GL
  • [6] Estimating worldwide effects of non-pharmaceutical interventions on COVID-19 incidence and population mobility patterns using a multiple-event study
    Askitas, Nikolaos
    Tatsiramos, Konstantinos
    Verheyden, Bertrand
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] The Impact of the COVID-19 Pandemic on the Uptake of Influenza Vaccine: UK-Wide Observational Study
    Bachtiger, Patrik
    Adamson, Alexander
    Chow, Ji-Jian
    Sisodia, Rupa
    Quint, Jennifer K.
    Peters, Nicholas S.
    [J]. JMIR PUBLIC HEALTH AND SURVEILLANCE, 2021, 7 (04):
  • [8] The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections
    Baker, Rachel E.
    Park, Sang Woo
    Yang, Wenchang
    Vecchi, Gabriel A.
    Metcalf, C. Jessica E.
    Grenfell, Bryan T.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (48) : 30547 - 30553
  • [9] Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussis
    Bayliss, Julianne
    Randhawa, Roshnee
    Oh, Kyu-Bin
    Kandeil, Walid
    Jenkins, Victoria A.
    Turriani, Elisa
    Nissen, Michael
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 344 - 350
  • [10] COVID-19 and seasonal influenza: The potential 2021-22 "Twindemic"
    Bellizzi, Saverio
    Napodano, Catello M. Panu
    Pinto, Sergio
    Pichierri, Giuseppe
    [J]. VACCINE, 2022, 40 (24) : 3286 - 3287